✷ Report Code: A01761 | Feb 2022 | Pages: 172 | ||
Tables: 95 | Charts: 49 |
|
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Implantable Defibrillators Market
Request Now !The global Implantable Defibrillators market size was valued at $3,300.00 million in 2020, and is projected to reach $5,612.62 million by 2030, registering a CAGR of 5.3% from 2021 to 2030. An implantable cardioverter-defibrillator (ICD) is a small battery-powered device placed in the chest to detect and stop irregular heartbeats (arrhythmias). An ICD continuously monitors the heartbeat and delivers electric shocks, when needed, to restore a regular heart rhythm. Patients need an ICD if they have a dangerously fast heartbeat that keeps the heart from supplying enough blood to the rest of the body (such as ventricular tachycardia or ventricular fibrillation) or if user is at high risk of such a heart rhythm problem (arrhythmia), usually because of a weak heart muscle.
The COVID-19 outbreak is anticipated to have a positive impact on growth of the global Implantable Defibrillators market. Rise in heart patients and cardiovascular diseases and as they are highly prone to get infected by COVID-19, and risk of sudden cardiac arrest (SCA) in COVID-19 patients are propelling the growth of the implantable defibrillators market during the pandemic.
An ICD differs from a pacemaker, which is an implantable device that can prevent dangerously slow heartbeats. A traditional ICD is implanted in the chest and the wires (leads) attach to the heart. Implant procedure requires invasive surgery. Whereas, a subcutaneous ICD (S-ICD) is another option, which is implanted under the skin at the side of the chest below the armpit. It is attached to an electrode that runs along the breastbone. An S-ICD is larger than a traditional ICD but does not attach to the heart.
The demand for implantable defibrillators is expected to increase globally during the forecast period, owing to rapid increase in geriatric population and rise in incidences of sudden cardiac arrest (SCA). However, factors such as lack of awareness toward the advantages of using implantable defibrillators, high cost of implantable defibrillators, and unfavorable reimbursement policies are anticipated to hamper the implantable defibrillator market growth. Rise in demand for ICDs for patients with nonischemic cardiomyopathy reduces the risk of mortality to around 23%, which is expected to offer new opportunities for the market players. The impact of driving factors is expected to surpass that of the restraints. Moreover, emergence of new technologies and increase in adoption of S-ICDs are anticipated to provide new growth opportunities in the future.
The COVID-19 pandemic has had a significant impact on the implantable defibrillators market. The COVID-19 outbreak positively influenced growth of the market. Rise in cases of coronavirus across the globe put a heavy strain on the healthcare sector. Rise in heart patients and cardiovascular diseases and as they are highly prone to get infected by COVID-19, there is a strong growth of heart implants during the pandemic. COVID-19 can affect the cardiovascular system, resulting in myocardial injury, arrhythmias, intravascular thrombosis, and sudden cardiac death. Reports have suggested association between COVID-19 activity and cardiac arrests in the community and within in‐hospital settings. Life-threatening arrhythmias have been variably reported among patients hospitalized for COVID-19 infection. Sudden cardiac arrest (SCA) in COVID-19 patients is an alarming concern for clinicians, which has amplified demand for implantable defibrillators. Defibrillator shock episodes have increased during the higher COVID-19 activity.
Implantable Defibrillators Market SegmentationThe implantable defibrillator market in this report is studied on the basis of product type and region. On the basis of product type, the market is divided into transvenous implantable cardioverter-defibrillator (T-ICDs), subcutaneous implantable cardioverter defibrillators (S-ICDS), and cardiac resynchronization therapy defibrillator (CRT-D). Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
By product type, the transvenous implantable cardioverter-defibrillator (T-ICDs) segment currently dominates the global implantable defibrillators market and is expected to continue during the forecast period as T-ICDs are the most commonly used devices to treat heart disorders for higher precision and targeted functioning.
Region wise, North America dominated the market in 2020, owing to a rise in the incidence of sudden cardiac arrest (SCA), increase in the adoption of S-ICDs, high purchasing power, and availability of advanced healthcare facilities. However, Asia-Pacific is expected to witness considerable implantable defibrillator market growth during the forecast period due to its high population base, increasing disposable incomes, and improvement in patient awareness about ICD devices.
The major companies profiled in this report include Abbott, Biotronik SE & Co. KG, Boston Scientific Corporation, Fukuda Denshi Co. Ltd., Imricor Medical Systems, Koninklijke Philips N.V., LivaNova Plc Company, Medtronic Plc, Microport scientific corporation, and Nihon Kohden Corporation.
Key Benefits For Stakeholders
Implantable Defibrillators Market Report Highlights
Aspects | Details |
---|---|
By Product Type |
|
By Region |
|
By Key Market Players |
|
CHAPTER 1: INTRODUCTION
1.1.Report Description
1.2.Key Market Segments
1.3.Key Benefits
1.4.Research Methodology
1.4.1.Primary Research
1.4.2.Secondary Research
1.4.3.Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1.CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1.Market Definition and Scope
3.2.Key Findings
3.2.1.Top Investment Pockets
3.2.2.Top Winning Strategies
3.3.Porter's Five Forces Analysis
3.3.1.Bargaining Power of Suppliers
3.3.2.Threat of New Entrants
3.3.3.Threat of Substitutes
3.3.4.Competitive Rivalry
3.3.5.Bargaining Power among Buyers
3.4.Market Share Analysis/Top Player Positioning
3.4.1.Market Share Analysis/Top Player Positioning 2020
3.5.Market Dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6. COVID-19 Impact Analysis
CHAPTER 4: IMPLANTABLE DEFIBRILLATORS MARKET, BY PRODUCT TYPE
4.1.Market Overview
4.1.1Market Size and Forecast, By Product Type
4.2.Transvenous Implantable Cardioverter-Defibrillator (T-ICDs)
4.2.1.Key Market Trends, Growth Factors and Opportunities
4.2.2.Market Size and Forecast, By Region
4.2.3.Market Share Analysis, By Country
4.3.Subcutaneous Implantable Cardioverter Defibrillators (S-ICDS)
4.3.1.Key Market Trends, Growth Factors and Opportunities
4.3.2.Market Size and Forecast, By Region
4.3.3.Market Share Analysis, By Country
4.4.Cardiac Resynchronization Therapy Defibrillator (CRT-D)
4.4.1.Key Market Trends, Growth Factors and Opportunities
4.4.2.Market Size and Forecast, By Region
4.4.3.Market Share Analysis, By Country
CHAPTER 5: IMPLANTABLE DEFIBRILLATORS MARKET, BY REGION
5.1.Market Overview
5.1.1Market Size and Forecast, By Region
5.2.North America
5.2.1.Key Market Trends and Opportunities
5.2.2.Market Size and Forecast, By Product Type
5.2.3.Market Size and Forecast, By Country
5.2.4.United States Implantable Defibrillators Market
5.2.4.1.Market Size and Forecast, By Product Type
5.2.5.Canada Implantable Defibrillators Market
5.2.5.1.Market Size and Forecast, By Product Type
5.2.6.Mexico Implantable Defibrillators Market
5.2.6.1.Market Size and Forecast, By Product Type
5.3.Europe
5.3.1.Key Market Trends and Opportunities
5.3.2.Market Size and Forecast, By Product Type
5.3.3.Market Size and Forecast, By Country
5.3.4.France Implantable Defibrillators Market
5.3.4.1.Market Size and Forecast, By Product Type
5.3.5.Germany Implantable Defibrillators Market
5.3.5.1.Market Size and Forecast, By Product Type
5.3.6.Italy Implantable Defibrillators Market
5.3.6.1.Market Size and Forecast, By Product Type
5.3.7.Spain Implantable Defibrillators Market
5.3.7.1.Market Size and Forecast, By Product Type
5.3.8.U.K Implantable Defibrillators Market
5.3.8.1.Market Size and Forecast, By Product Type
5.3.9.Rest Of Europe Implantable Defibrillators Market
5.3.9.1.Market Size and Forecast, By Product Type
5.4.Asia-Pacific
5.4.1.Key Market Trends and Opportunities
5.4.2.Market Size and Forecast, By Product Type
5.4.3.Market Size and Forecast, By Country
5.4.4.China Implantable Defibrillators Market
5.4.4.1.Market Size and Forecast, By Product Type
5.4.5.Japan Implantable Defibrillators Market
5.4.5.1.Market Size and Forecast, By Product Type
5.4.6.India Implantable Defibrillators Market
5.4.6.1.Market Size and Forecast, By Product Type
5.4.7.South Korea Implantable Defibrillators Market
5.4.7.1.Market Size and Forecast, By Product Type
5.4.8.Australia Implantable Defibrillators Market
5.4.8.1.Market Size and Forecast, By Product Type
5.4.9.Rest of Asia Pacific Implantable Defibrillators Market
5.4.9.1.Market Size and Forecast, By Product Type
5.5.LAMEA
5.5.1.Key Market Trends and Opportunities
5.5.2.Market Size and Forecast, By Product Type
5.5.3.Market Size and Forecast, By Country
5.5.4.Brazil Implantable Defibrillators Market
5.5.4.1.Market Size and Forecast, By Product Type
5.5.5.South Africa, Implantable Defibrillators Market
5.5.5.1.Market Size and Forecast, By Product Type
5.5.6.Saudi Arabia Implantable Defibrillators Market
5.5.6.1.Market Size and Forecast, By Product Type
5.5.7.Rest of LAMEA Implantable Defibrillators Market
5.5.7.1.Market Size and Forecast, By Product Type
CHAPTER 6: COMPANY PROFILES
6.1.Abbott Laboratories
6.1.1.Company Overview
6.1.2.Key Executives
6.1.3.Company snapshot
6.1.4.Operating business segments
6.1.5.Product portfolio
6.1.6.Business Performance
6.1.7.Key Strategic Moves and Developments
6.2.Biotronik Schweiz Ag
6.2.1.Company Overview
6.2.2.Key Executives
6.2.3.Company snapshot
6.2.4.Operating business segments
6.2.5.Product portfolio
6.2.6.Business Performance
6.2.7.Key Strategic Moves and Developments
6.3.Boston Scientific Corporation
6.3.1.Company Overview
6.3.2.Key Executives
6.3.3.Company snapshot
6.3.4.Operating business segments
6.3.5.Product portfolio
6.3.6.Business Performance
6.3.7.Key Strategic Moves and Developments
6.4.FUKUDA DENSHI CO. Ltd
6.4.1.Company Overview
6.4.2.Key Executives
6.4.3.Company snapshot
6.4.4.Operating business segments
6.4.5.Product portfolio
6.4.6.Business Performance
6.4.7.Key Strategic Moves and Developments
6.5.IMRICOR MEDICAL SYSTEMS
6.5.1.Company Overview
6.5.2.Key Executives
6.5.3.Company snapshot
6.5.4.Operating business segments
6.5.5.Product portfolio
6.5.6.Business Performance
6.5.7.Key Strategic Moves and Developments
6.6.Koninklijke Philips N.V.
6.6.1.Company Overview
6.6.2.Key Executives
6.6.3.Company snapshot
6.6.4.Operating business segments
6.6.5.Product portfolio
6.6.6.Business Performance
6.6.7.Key Strategic Moves and Developments
6.7.LivaNova PLC
6.7.1.Company Overview
6.7.2.Key Executives
6.7.3.Company snapshot
6.7.4.Operating business segments
6.7.5.Product portfolio
6.7.6.Business Performance
6.7.7.Key Strategic Moves and Developments
6.8.Medtronic Plc.
6.8.1.Company Overview
6.8.2.Key Executives
6.8.3.Company snapshot
6.8.4.Operating business segments
6.8.5.Product portfolio
6.8.6.Business Performance
6.8.7.Key Strategic Moves and Developments
6.9.Microport Scientific Corp
6.9.1.Company Overview
6.9.2.Key Executives
6.9.3.Company snapshot
6.9.4.Operating business segments
6.9.5.Product portfolio
6.9.6.Business Performance
6.9.7.Key Strategic Moves and Developments
6.10.Nohen Kohden Corporation
6.10.1.Company Overview
6.10.2.Key Executives
6.10.3.Company snapshot
6.10.4.Operating business segments
6.10.5.Product portfolio
6.10.6.Business Performance
6.10.7.Key Strategic Moves and Developments
LIST OF TABLES
TABLE 1.GLOBAL IMPLANTABLE DEFIBRILLATORS MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 2.GLOBAL IMPLANTABLE DEFIBRILLATORS MARKET FOR TRANSVENOUS IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR (T-ICDS), BY REGION, 2020-2030 ($MILLION)
TABLE 3.GLOBAL IMPLANTABLE DEFIBRILLATORS MARKET FOR SUBCUTANEOUS IMPLANTABLE CARDIOVERTER DEFIBRILLATORS (S-ICDS), BY REGION, 2020-2030 ($MILLION)
TABLE 4.GLOBAL IMPLANTABLE DEFIBRILLATORS MARKET FOR CARDIAC RESYNCHRONIZATION THERAPY DEFIBRILLATOR (CRT-D), BY REGION, 2020-2030 ($MILLION)
TABLE 5.GLOBAL IMPLANTABLE DEFIBRILLATORS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 6.NORTH AMERICA IMPLANTABLE DEFIBRILLATORS, BY Region, 2020-2030 ($MILLION)
TABLE 7.NORTH AMERICA IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 8.UNITED STATES IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 9.CANADA IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 10.MEXICO IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 11.EUROPE IMPLANTABLE DEFIBRILLATORS, BY Region, 2020-2030 ($MILLION)
TABLE 12.EUROPE IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 13.FRANCE IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 14.GERMANY IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 15.ITALY IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 16.SPAIN IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 17.UNITED KINGDOM IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 18.REST OF EUROPE IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 19.ASIA-PACIFIC IMPLANTABLE DEFIBRILLATORS, BY Region, 2020-2030 ($MILLION)
TABLE 20.ASIA-PACIFIC IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 21.CHINA IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 22.JAPAN IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 23.INDIA IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 24.SOUTH KOREA IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 25.AUSTRALIA IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 26.REST OF ASIA PACIFIC IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 27.LAMEA IMPLANTABLE DEFIBRILLATORS, BY Region, 2020-2030 ($MILLION)
TABLE 28.LAMEA IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 29.BRAZIL IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 30.SOUTH AFRICA, IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 31.SAUDI ARABIA IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 32.REST OF LAMEA IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 33.ABBOTT LABORATORIES: KEY EXECUTIVES
TABLE 34.ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 35.ABBOTT LABORATORIES: OPERATING SEGMENTS
TABLE 36.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 37.ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 38.BIOTRONIK SCHWEIZ AG: KEY EXECUTIVES
TABLE 39.BIOTRONIK SCHWEIZ AG: COMPANY SNAPSHOT
TABLE 40.BIOTRONIK SCHWEIZ AG: OPERATING SEGMENTS
TABLE 41.BIOTRONIK SCHWEIZ AG: PRODUCT PORTFOLIO
TABLE 42.BIOTRONIK SCHWEIZ AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 43.BOSTON SCIENTIFIC CORPORATION: KEY EXECUTIVES
TABLE 44.BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
TABLE 45.BOSTON SCIENTIFIC CORPORATION: OPERATING SEGMENTS
TABLE 46.BOSTON SCIENTIFIC CORPORATION: PRODUCT PORTFOLIO
TABLE 47.BOSTON SCIENTIFIC CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 48.FUKUDA DENSHI CO.,LTD: KEY EXECUTIVES
TABLE 49.FUKUDA DENSHI CO.,LTD: COMPANY SNAPSHOT
TABLE 50.FUKUDA DENSHI CO.,LTD: OPERATING SEGMENTS
TABLE 51.FUKUDA DENSHI CO.,LTD: PRODUCT PORTFOLIO
TABLE 52.FUKUDA DENSHI CO.,LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 53.IMRICOR MEDICAL SYSTEMS: KEY EXECUTIVES
TABLE 54.IMRICOR MEDICAL SYSTEMS: COMPANY SNAPSHOT
TABLE 55.IMRICOR MEDICAL SYSTEMS: OPERATING SEGMENTS
TABLE 56.IMRICOR MEDICAL SYSTEMS: PRODUCT PORTFOLIO
TABLE 57.IMRICOR MEDICAL SYSTEMS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 58.KONINKLIJKE PHILIPS N.V.: KEY EXECUTIVES
TABLE 59.KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT
TABLE 60.KONINKLIJKE PHILIPS N.V.: OPERATING SEGMENTS
TABLE 61.KONINKLIJKE PHILIPS N.V.: PRODUCT PORTFOLIO
TABLE 62.KONINKLIJKE PHILIPS N.V.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 63.LIVANOVA PLC: KEY EXECUTIVES
TABLE 64.LIVANOVA PLC: COMPANY SNAPSHOT
TABLE 65.LIVANOVA PLC: OPERATING SEGMENTS
TABLE 66.LIVANOVA PLC: PRODUCT PORTFOLIO
TABLE 67.LIVANOVA PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 68.MEDTRONIC PLC: KEY EXECUTIVES
TABLE 69.MEDTRONIC PLC: COMPANY SNAPSHOT
TABLE 70.MEDTRONIC PLC: OPERATING SEGMENTS
TABLE 71.MEDTRONIC PLC: PRODUCT PORTFOLIO
TABLE 72.MEDTRONIC PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 73.MICROPORT SCIENTIFIC CORP: KEY EXECUTIVES
TABLE 74.MICROPORT SCIENTIFIC CORP: COMPANY SNAPSHOT
TABLE 75.MICROPORT SCIENTIFIC CORP: OPERATING SEGMENTS
TABLE 76.MICROPORT SCIENTIFIC CORP: PRODUCT PORTFOLIO
TABLE 77.MICROPORT SCIENTIFIC CORP: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 78.NOHEN KOHDEN CORPORATION: KEY EXECUTIVES
TABLE 79.NOHEN KOHDEN CORPORATION: COMPANY SNAPSHOT
TABLE 80.NOHEN KOHDEN CORPORATION: OPERATING SEGMENTS
TABLE 81.NOHEN KOHDEN CORPORATION: PRODUCT PORTFOLIO
TABLE 82.NOHEN KOHDEN CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 1.GLOBAL IMPLANTABLE DEFIBRILLATORS MARKET SEGMENTATION
FIGURE 2.GLOBAL IMPLANTABLE DEFIBRILLATORS MARKET
FIGURE 3.SEGMENTATION IMPLANTABLE DEFIBRILLATORS MARKET
FIGURE 4.TOP INVESTMENT POCKET IN IMPLANTABLE DEFIBRILLATORS MARKET
FIGURE 5.TOP WINNING STRATEGIES, 2019-2021*
FIGURE 6.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019-2021(%)
FIGURE 7.TOP WINNING STRATEGIES, BY COMPANY, 2019-2021*
FIGURE 8.MODERATE BARGAINING POWER OF BUYERS
FIGURE 9.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 10.MODERATE THREAT OF NEW ENTRANTS
FIGURE 11.LOW THREAT OF SUBSTITUTION
FIGURE 12.HIGH COMPETITIVE RIVALRY
FIGURE 13.TOP PLAYER POSITIONING, 2020
FIGURE 14.MARKET SHARE ANALYSIS, 2020
FIGURE 15.RESTRAINTS AND DRIVERS: IMPLANTABLE DEFIBRILLATORS MARKET
FIGURE 16.IMPLANTABLE DEFIBRILLATORS MARKET SEGMENTATION, BY PRODUCT TYPE
FIGURE 17.IMPLANTABLE DEFIBRILLATORS MARKET FOR TRANSVENOUS IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR (T-ICDS), BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 18.IMPLANTABLE DEFIBRILLATORS MARKET FOR SUBCUTANEOUS IMPLANTABLE CARDIOVERTER DEFIBRILLATORS (S-ICDS), BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 19.IMPLANTABLE DEFIBRILLATORS MARKET FOR CARDIAC RESYNCHRONIZATION THERAPY DEFIBRILLATOR (CRT-D), BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 20.ABBOTT LABORATORIES: NET SALES, 2018-2020 ($MILLION)
FIGURE 21.ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 22.ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 23.BIOTRONIK SCHWEIZ AG: NET SALES, 2018-2020 ($MILLION)
FIGURE 24.BIOTRONIK SCHWEIZ AG: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 25.BIOTRONIK SCHWEIZ AG: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 26.BOSTON SCIENTIFIC CORPORATION: NET SALES, 2018-2020 ($MILLION)
FIGURE 27.BOSTON SCIENTIFIC CORPORATION: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 28.BOSTON SCIENTIFIC CORPORATION: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 29.FUKUDA DENSHI CO.,LTD: NET SALES, 2018-2020 ($MILLION)
FIGURE 30.FUKUDA DENSHI CO., LTD: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 31.FUKUDA DENSHI CO., LTD: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 32.IMRICOR MEDICAL SYSTEMS: NET SALES, 2018-2020 ($MILLION)
FIGURE 33.IMRICOR MEDICAL SYSTEMS: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 34.IMRICOR MEDICAL SYSTEMS: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 35.KONINKLIJKE PHILIPS N.V.: NET SALES, 2018-2020 ($MILLION)
FIGURE 36.KONINKLIJKE PHILIPS N.V.: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 37.KONINKLIJKE PHILIPS N.V.: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 38.LIVANOVA PLC: NET SALES, 2018-2020 ($MILLION)
FIGURE 39.LIVANOVA PLC: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 40.LIVANOVA PLC: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 41.MEDTRONIC PLC: NET SALES, 2018-2020 ($MILLION)
FIGURE 42.MEDTRONIC PLC: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 43.MEDTRONIC PLC: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 44.MICROPORT SCIENTIFIC CORP: NET SALES, 2018-2020 ($MILLION)
FIGURE 45.MICROPORT SCIENTIFIC CORP: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 46.MICROPORT SCIENTIFIC CORP: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 47.NOHEN KOHDEN CORPORATION: NET SALES, 2018-2020 ($MILLION)
FIGURE 48.NOHEN KOHDEN CORPORATION: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 49.NOHEN KOHDEN CORPORATION: REVENUE SHARE, BY REGION, 2020 (%)
According to the analyst’s perspective, the implantable defibrillators market has witnessed rapid growth in recent years, owing to factors such as rise in incidences of chronic heart diseases and increase in awareness regarding development of implantable defibrillators that prevents sudden cardiac arrest (SCA) in patients that have sustained ventricular tachycardia or atrial fibrillation. The implantable defibrillators market has gained interest of healthcare professionals as they allow them to monitor and treat sudden cardiac arrest (SCA) by analyzing patient heart rhythm and deliver shock required to restore its functioning. Therefore, ICDs constantly monitor heart rhythm through electrodes and deliver treatments when abnormal heart rhythm is diagnosed.
Treatments through ICDs include pacing, cardioversion, and defibrillation to restore normal heart rhythm. Furthermore, increase in geriatric population and rise in use of devices to manage congestive heart failure are expected to drive growth of the market. Advanced technologies such as longer battery life, quadripolar leads, reduced inappropriate shocks, and less invasive installation of implantable defibrillators propel demand to greater extent. However, lack of awareness about these devices in developing economies is expected to restrain the market growth.
A. An implantable cardioverter-defibrillator (ICD) is a small battery-powered device placed in the chest to detect and stop irregular heartbeats (arrhythmias).
A. The total market value of Global Implantable Defibrillators Market is $3,300.00 million in 2020.
A. The forecast period for Global Implantable Defibrillators Market is 2021 to 2030.
A. The market value of Global Implantable Defibrillators Market in 2030 is $5,612.62 million.
A. Abbott, Koninklijke Philips N.V., Medtronic Plc., Nihon Kohden Corporation, and Boston Scientific Corporation held a high market position owing to the strong geographical foothold in different regions.
A. Subcutaneous Implantable Cardioverter Defibrillators (S-Icds) segment dominates the global market, as T-ICDs are the most commonly used devices to treat heart disorders for higher precision and targeted functioning.
A. The major factor for the growth of global Implantable Defibrillators market are rise in incidences of heart disorders and advancements in technology such as S-ICDs developed as an alternative to conventional T-ICDs with less potential hazards.
A. Owing to rise in the geriatric population in the market. Furthermore, rapidly increasing aging population and subsequent rise in the number of cardiac patients.
A. The base year is 2020 in Global Implantable Defibrillators Market.
A. Implantable Defibrillators are used to detect and stop irregular heartbeats (arrhythmias).
Start reading instantly.
This Report and over 66,782+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers